Johnson & Johnson

NYSE:JNJ   11:40:24 AM EDT
179.20
-0.26 (-0.14%)
Products

ViiV Healthcare Announce FDA Approval Of Cabenuva For Virologically Suppressed Adolescents Living With HIV Who Are 12 Years Of Age Or Older And Weigh At Least 35 KG

Published: 03/29/2022 17:45 GMT
Johnson & Johnson (JNJ) - Viiv Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, Rilpivirine) for Virologically Suppressed Adolescents Living With Hiv Who Are 12 Years of Age Or Older and Weigh at Least 35 Kg.
Viiv Healthcare - FDA Approved Cabenuv for Treatment of Hiv-1 in Virologically Suppressed Adolescents Who Are 12 Years of Age Or Older.